Seres Therapeutics (MCRB) Assets Average (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Assets Average for 11 consecutive years, with $140.8 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 11.58% to $140.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $140.8 million through Dec 2025, down 11.58% year-over-year, with the annual reading at $139.0 million for FY2025, 44.22% down from the prior year.
  • Assets Average hit $140.8 million in Q4 2025 for Seres Therapeutics, down from $143.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $387.0 million in Q3 2023 to a low of $140.8 million in Q4 2025.
  • Historically, Assets Average has averaged $282.8 million across 5 years, with a median of $316.9 million in 2021.
  • Biggest five-year swings in Assets Average: surged 172.29% in 2021 and later tumbled 56.56% in 2025.
  • Year by year, Assets Average stood at $375.6 million in 2021, then fell by 12.05% to $330.3 million in 2022, then increased by 9.94% to $363.1 million in 2023, then crashed by 56.14% to $159.3 million in 2024, then fell by 11.58% to $140.8 million in 2025.
  • Business Quant data shows Assets Average for MCRB at $140.8 million in Q4 2025, $143.6 million in Q3 2025, and $154.0 million in Q2 2025.